Search Results

CB 300919 50mg 50mg  | Purity Not Available

Adooq Bioscience

CB 300919 is a potential therapy for ovarian cancer. Preclinical data showed that this quinazoline-based compound CB 300919 has a continuous exposure (96 h) growth inhibition IC50 value of 2 nM in human CH1 ovarian tumor xenograft

More Information Supplier Page

CB 300919 5mg 5mg  | Purity Not Available

Adooq Bioscience

CB 300919 is a potential therapy for ovarian cancer. Preclinical data showed that this quinazoline-based compound CB 300919 has a continuous exposure (96 h) growth inhibition IC50 value of 2 nM in human CH1 ovarian tumor xenograft

More Information Supplier Page

CB 300919 25mg 25mg  | Purity Not Available

Adooq Bioscience

CB 300919 is a potential therapy for ovarian cancer. Preclinical data showed that this quinazoline-based compound CB 300919 has a continuous exposure (96 h) growth inhibition IC50 value of 2 nM in human CH1 ovarian tumor xenograft

More Information Supplier Page

CB 300919 10mg 10mg  | Purity Not Available

Adooq Bioscience

CB 300919 is a potential therapy for ovarian cancer. Preclinical data showed that this quinazoline-based compound CB 300919 has a continuous exposure (96 h) growth inhibition IC50 value of 2 nM in human CH1 ovarian tumor xenograft

More Information Supplier Page

CC-401 5mg 5mg  | Purity Not Available

Adooq Bioscience

CC-401 is a second generation ATP-competitive anthrapyrazolone c-Jun N terminal kinase (JNK) inhibitor with potential antineoplastic activity.

More Information Supplier Page

CC-401 25mg 25mg  | Purity Not Available

Adooq Bioscience

CC-401 is a second generation ATP-competitive anthrapyrazolone c-Jun N terminal kinase (JNK) inhibitor with potential antineoplastic activity.

More Information Supplier Page

CC-401 2mg 2mg  | Purity Not Available

Adooq Bioscience

CC-401 is a second generation ATP-competitive anthrapyrazolone c-Jun N terminal kinase (JNK) inhibitor with potential antineoplastic activity.

More Information Supplier Page